Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer | New England Journal of Medicine

RT @NEJM: ESOPEC, a large randomized trial involving patients with resectable esophageal cancer, showed that perioperative chemotherapy imp…

RT @ArndtVogel: CTx + sintilimab vs chemoradiotherapy + sintilimab vs chemoradiotherapy for neoadj. treatment in resectable locally advance…

RT @DrDespina123: Excited to present our latest research at the 2025 GI @ASCO Symposium! Check out our posters on cutting-edge immunotherap…

RT @Schadi_CRS: @UqbaKhan on the use of ctDNA in the management of our colon cancer patients. Take away points - ctDNA - good prognostic u…

@Schadi_CRS @TemertySimCtr Thank you @Schadi_CRS. It was great to be there. It was an amazing meeting!

RT @Schadi_CRS: @UqbaKhan does an excellent job demonstrating the evidence for I/O in dMMR and pMMR colon cancers. Still not NCCN accepted…

RT @NEJM: #ESMO24 Round Up: 11 articles were simultaneously published in NEJM and presented at this year’s @myESMO Congress in Barcelona, S…

RT @NEJM: Presented at #ESMO24: Cabozantinib, as compared with placebo, doubled progression-free survival in patients with extrapancreatic…

RT @mdmanishshah: Pooled data across over 1000 patients clearly show benefit of targeting CLDN18.2 in gastric cancer. #Amazing things ar…

RT @ArndtVogel: Updated data for atezo + bev vs surveillance in resected or ablated high risk HCC #ESMO24 🔎IMbrave050 👉RFS 33.2 vs 36 mo, H…

mFOLFIRINOX with conventional CRT did not improve R0 nor OS compared to mFOLFIRINOX without preoperative CRT in patients with BRPC. @myESMO

IMBrave050 updated results did not hold the initial RFS benefit in HCC post resection. Adjuvant Atezo/Bev therapy should not be used based on this update! @myESMO

RT @Olympics: #OLYMPICRECORD FOR ARSHAD NADEEM! 🇵🇰 @Worldathletics | #Athletics #Paris2024 | #OMEGA | #OMEGAOfficialTimekeeper https://t.c…

RT @mdmanishshah: Happy to report our analysis of CLDN18.2 expression globally! Important for those who will receive CLDN18.2 targeted Rx…

RT @MallaMidhun: We came a long way in the management of HCC over the past decade. Increased proportion of patient being cured. Exciting pr…

RT @OncoThor: It’s out! The results of NETTER-2. Upfront PRRT for G2 (Ki67 10 or more) and G3 NETs. Much higher ORR than in the lower grade…

RT @MyriamChalabi: Ecstatic and proud to share the NICHE-2 results, now published in @NEJM. Out of 111 pts, 95% had an MPR , and 68% a pCR…

RT @astrowalanmd: Honored to have presented “Why Hope?” at outstanding #ASCO24 panel on “The Art and Science of Hope” with ⁦@ARosen380⁩ @Ma…

RT @OncoThor: Surgery for liver AND peritoneal NET mets...? Another excellent study led by @HallberaG. Long-term OS and symptom control out…